GUERBET FINANCIAL REPORT
FIRST HALF 2020
AT JUNE 30, 2020
PERIOD ENDED JUNE 30, 2020 | Page: 2/27 | |
HALF-YEAR FINANCIAL REPORT | ||
CONTENTS
ACTIVITY REPORT ………………………………………………………………………………………………………….. 4
PERIOD ENDED JUNE 30, 2020 | Page: 4/27 | |
HALF-YEAR FINANCIAL REPORT | ||
ACTIVITY REPORT
Comments on activity in the first half of 2020
Europe and the Americas impacted by the health crisis, good sales in Asia
The health crisis had a major impact on the first half of the year. Since the crisis began, Guerbet has taken swift action to ensure employee safety and business continuity. All of the Group's production plants and logistics centers around the world continued to operate.
The postponement of non-essential radiological examinations and procedures by radiologists, combined with spontaneous cancellations by certain patients and the increase in longer disinfection and protection measures due to SARS-Cov-2, impacted activity, especially MRI but also CT/Cath Lab.
The development of artificial intelligence solutions and digital solutions continued without any impact on project progress or on their actual market release date. Regarding Gadopiclenol, the recruitment of phase IIIb patients was logically slowed down during the lockdown, delaying the process in progress accordingly. The market release is still planned for the first part of 2023.
Revenue was €363.7 million at June 30, down 9.2% compared with the first half of 2019, including an unfavorable forex impact of €3.4 million (€367.1 at constant exchange rates). This decrease at constant exchange rates was driven by sales drop of 21.2% in Europe and 13.6% in the Americas. In Asia, the implementation of Go-Direct in Japan and good sales in China led to 9% increase.
Diagnostic Imaging revenue was €308.4 million, compared with €354.6 million in the first half of 2019, down 13.0% (-11.9% at CER). The main reason was the impact of the health crisis following the lockdown in most countries.
- MRI sales decreased 18.7% (identical at constant exchange rates) to €110.9 million;
- CT/Cath Lab revenue was down 9.7% at €196.0 million with reduced volumes across all products in the range except for Xenetix® used in some countries for the diagnostic of the most serious Covid cases (At CER, revenue for the half-year period was €199.9 million, down -7.9%).
Interventional Imaging continued to be driven by Lipiodol® sales. Its revenue totaled €36 million, up 3.1% (+1.9% at CER) from €34.9 million in the same period last year.
PERIOD ENDED JUNE 30, 2020 | Page: 5/27 | |
HALF-YEAR FINANCIAL REPORT | ||
Satisfactory results under unprecedented health conditions |
In millions of euros | H1 2019 | H1 2020 | ||||||
Consolidated financial statements (IFRS) | ||||||||
Revenue | 400.6 | 363.7 | ||||||
EBITDA (2) | 61.6 | 53.3 | ||||||
% of revenue | 15.4% | 14.7% | ||||||
Operating income | 22.3 | 25.4 | ||||||
% of revenue | 5.6% | 7.0% | ||||||
Net income | 19.0 | 8.2 | ||||||
% of revenue | 4.8% | 2.3% | ||||||
Net Debt | 358.1 | 269.3 | ||||||
The financial statements for the first half of 2020, approved by the Board of Directors on 23 September 2020, underwent a limited review by the statutory auditors. The statutory auditors' report is currently being drawn up.
EBITDA stood at €53.3 million compared with €61.6 million in the first half of 2019. However, it represents 14.7% of revenue for the period, which was a satisfactory performance for the Group given the significant drop in activity.
The EBITDA margin rate was maintained thanks to strict budgetary discipline. It concerned sales and marketing costs and the acceleration of the "Cost to Win" plan. The total reduction of expenditures over the first half of the year was around €20 million.
As of June 30, 2020, operating income totaled €25.4 million and represented 7.0% of revenue. Net income was €8.2 million compared with €19.0 million at June 30, 2019. This decrease between the two periods is primarily explained by significant favorable forex gains in 2019 as well as the write-down of the Canadian subsidiary's assets in June 2020 for €5.7 million in anticipation of the sale of the Montreal production plant on July 15, 2020, associated with the agreed sale price.
Sound financial structure
As of June 30, 2020, shareholders' equity amounted to €374.9 million compared with €367.9 million for the same period last year. The Group has reduced its debt dramatically. At the end of June, the net debt/EBITDA ratio was 2.61 compared with 3.06 at June 30, 2019. This improvement brought net debt to €269.3 million at June 30, 2020, compared with €358.1 million at the end of the first half of 2019.
Stronger governance
To accelerate its transformation and achieve its strategic ambitions, the Group recently announced the reinforcement of its Executive Committee with four new functions dedicated to Diagnostic Imaging and Interventional Imaging franchises and its Asia-Pacific, Americas, and EMEA regions.
PERIOD ENDED JUNE 30, 2020 | Page: 6/27 | |
HALF-YEAR FINANCIAL REPORT | ||
2020 outlook
The future of the health situation remains uncertain, and the gradual upturn in activity is still inconsistent. July benefited from a restocking effect, but activity fell in August.
In the coming months, the Group's activity is expected to be affected by the initial sales of the generic of Dotarem® in the United States. The Group believes that the change in Dotarem® volumes and prices should be comparable with Europe, where the generic has already been available for more than two years. Moreover, Guerbet should continue to benefit from the good performance of Lipiodol® and the strength of Xenetix® and Optiray®.
Given the impact of the generic and against the backdrop of a stabilized health crisis with normal operation of the healthcare system, the Group expects second-half revenue to be largely comparable with the first-half revenue, down 12% compared with 2019 at constant exchange rates. On this basis, the Group expects EBITDA for the 2020 financial year to be around 14% of revenue.
Lastly, the Group is confident that it can lower its level of structural costs for the long term with expectations of a very favorable impact on profitability once business is back to normal.
- At constant exchange rates: amounts and rates of growth are calculated by canceling out the exchange rate effect, which is defined as the difference between the indicator's value for period N, converted at the exchange rate for period N-1, and the indicator's value for period N-1.
- EBITDA refers to operating income with the net allowance for amortization, depreciation, and provisions added back in.
Main risks and uncertainties for the remaining six months of the year
Readers can refer to the 2019 Universal Registration Document filed with the French financial markets authority (AMF) on April 28, 2020, under number D.20-0369. It can be viewed directly on the websites of the AMF and Guerbet (http://www.guerbet.com).
Since the beginning of 2020, the Guerbet group has faced the global COVID-19 health crisis. Detailed information is presented in chapter 3 "Highlights of the first half of 2020" of this document.
Main related-party transactions recorded in the first months of the year
Readers can refer to note 25 to the consolidated financial statements and note 31 (describing the list of stakes held by the parent company) of the 2019 Universal Registration Document filed with the French financial markets authority (AMF) on April 28, 2020, under number D.20-0369, which can be viewed directly on the websites of the AMF and Guerbet (http://www.guerbet.com).
PERIOD ENDED JUNE 30, 2020 | Page: 7/27 | |
HALF-YEAR FINANCIAL REPORT | ||
KEY FIGURES
In thousands of euros - IFRS | June 30, 2020 | June 30, 2019 |
Revenue | 363,651 | 400,566 |
EBITDA 1 | 53,288 | 61,635 |
Current operating income | 25,400 | 22,268 |
Net income | 8,199 | 19,031 |
Net earnings per share | €0.65 | €1.51 |
Shareholders' equity | 374,880 | 367,882 |
Net financial debt | 269,312 | 358,054 |
Net financial debt/EBITDA 2 | 2.61 | 3.06 |
Net financial debt/Shareholders' equity | 0.72 | 0.97 |
- EBITDA refers to operating income plus amortization, depreciation, and provisions.
- Calculation of rolling EBITDA based on the last 12 months and on net financial debt, including debt and amortization and depreciation expenses (IFRS 16).
PERIOD ENDED JUNE 30, 2020 | Page: 8/27 | |
HALF-YEAR FINANCIAL REPORT | ||
GUERBET STOCK
Month | Highest price in a | Lowest price in | Number of shares | Trading volume | |
trading session | a trading | traded | |||
(in €) | session (in €) | ||||
(in € million) | |||||
January | 58.1 | 49.6 | 112,584 | 6.04 | |
February | 56.3 | 50.1 | 73,794 | 3.84 | |
March | 54.9 | 47.0 | 86,425 | 4.42 | |
April | 57.2 | 52.4 | 59,606 | 3.28 | |
May | 55.1 | 46.0 | 60,477 | 3.03 | |
June | 49.8 | 46.2 | 73,756 | 3.49 | |
2019 | |||||
July | 56.4 | 47.3 | 136,857 | 3.84 | |
August | 56.0 | 48.8 | 119,681 | 6.13 | |
September | 52.0 | 45.3 | 82,728 | 6.87 | |
October | 51.3 | 45.6 | 117,376 | 5.54 | |
November | 53.0 | 49.9 | 79,761 | 4.15 | |
December | 54.0 | 41.0 | 229,950 | 10.46 | |
January | 44.1 | 34.1 | 287,090 | 11.46 | |
February | 37.7 | 31.7 | 176,790 | 6.25 | |
March | 34.4 | 26.2 | 197,622 | 5.84 | |
2020 | |||||
April | 30.9 | 26.0 | 135,074 | 3.91 | |
May | 35.0 | 27.8 | 127,008 | 4.00 | |
June | 38.0 | 33.3 | 103,677 | 3.68 | |
PERIOD ENDED JUNE 30, 2020 | Page: 9/27 | |
HALF-YEAR FINANCIAL REPORT | ||
CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS
AT JUNE 30, 2020
In thousands of euros (€K)
On September 23, 2020, the Board of Directors approved the publication of Guerbet's condensed consolidated half-year financial statements for the period from January 1 to June 30, 2020.
The condensed consolidated half-year financial statements at June 30, 2020, are to be read in conjunction with the consolidated financial statements for the financial year ended December 31, 2019, as indicated in the Universal Registration Document filed with the French financial market authority (AMF) on April 28, 2020, under number D.20-0369.
PERIOD ENDED JUNE 30, 2020 | Page: 10/27 | |
HALF-YEAR FINANCIAL REPORT | ||
1. Summary statements | ||
1.1 Consolidated balance sheet |
ASSETS (net) | |||
Notes | 6/30/2020 | 12/31/2019 | |
(in thousands of €) | |||
Intangible assets | 1 | 193,166 | 189,754 |
Tangible assets | 1 | 259,435 | 272,779 |
Other non-current financial assets | 16,208 | 15,933 | |
Deferred tax assets | 15,041 | 15,171 | |
Total non-current assets | 483,850 | 493,636 | |
Inventories | 2 | 220,956 | 236,593 |
Trade receivables | 118,518 | 140,344 | |
Assets held for sale | 7 & 11 | 12,871 | 0 |
Other current financial assets | 51,150 | 56,874 | |
Cash and cash equivalents | 77,490 | 81,420 | |
Total current assets | 480,984 | 515,231 | |
TOTAL ASSETS | 964,834 | 1,008,868 | |
EQUITY & LIABILITIES (net) | |||
Notes | 6/30/2020 | 12/31/2019 | |
(in thousands of €) | |||
Capital | 3 | 12,599 | 12,596 |
Other reserves | 403,777 | 375,743 | |
Net income | 8,199 | 37,328 | |
Translation adjustment | (49,694) | (36,474) | |
Equity, group share | 374,880 | 389,192 | |
of which Group share | 374,880 | 389,192 | |
Non-current financial debt (*) | 5 | 314,899 | 340,655 |
Other non-current financial liabilities | (1) | 1,913 | |
Deferred tax liabilities | 18,207 | 21,876 | |
Non-current provisions | 4 | 39,605 | 39,303 |
Non-current liabilities | 372,710 | 403,747 | |
Trade and other payables | 67,168 | 67,758 | |
Current financial debt | 5 | 31,903 | 37,252 |
Other current liabilities | 100,298 | 98,051 | |
Tax liabilities payable | 10,178 | 8,746 | |
Other short-term provisions | 4 | 3,765 | 4,122 |
Liabilities associated with assets held for sale | 7 & 11 | 3,931 | 0 |
Total current liabilities | 217,243 | 215,929 | |
TOTAL EQUITY & LIABILITIES | 964,834 | 1,008,868 |
(*) IFRS 5 impact of the sale of the Canadian subsidiary - see notes 7 and 11.
PERIOD ENDED JUNE 30, 2020 | Page: 11/27 | |
HALF-YEAR FINANCIAL REPORT | ||
1.2 Consolidated income statement |
(in thousands of €) | 6/30/2020 | 6/30/2019 |
(6 months) | (6 months) | |
Revenue | 363,651 | 400,566 |
Royalties | 0 | 0 |
Other operating revenue | 5,288 | 2,161 |
Purchases consumed and change in inventories | (85,679) | (79,376) |
Staff-related costs | (123,852) | (123,119) |
External charges | (100,270) | (129,832) |
Taxes and duties | (9,881) | (10,248) |
Depreciation and amortization | (30,711) | (29,580) |
Net allowances for provisions | 2,823 | (9,788) |
Other operating income and expenses | 4,031 | 1,484 |
Current operating income | 25,400 | 22,268 |
of which equity interests | (421) | (674) |
Income from cash and cash equivalents | 32 | 10 |
Gross finance costs | (4,477) | (5,235) |
Net finance costs | (4,446) | (5,226) |
Currency gains/losses | (4,847) | 7,874 |
Other financial income and expenses (*) | (5,123) | (195) |
Income taxes | (2,785) | (5,691) |
Consolidated net income | 8,199 | 19,031 |
of which group share | 8,199 | 19,031 |
Net earnings per share with €1 face value (in euros) | 0.65 | 1.51 |
Diluted net earnings per share with €1 face value (in euros) | 0.65 | 1.50 |
- Including €(5,202) K related to the IFRS 5 impact of the sale of the Canadian subsidiary - see notes 7 and 11.
PERIOD ENDED JUNE 30, 2020 | Page: 12/27 | |
HALF-YEAR FINANCIAL REPORT | ||
1.3 Statement of net income and gains and losses recognized directly in equity |
(in thousands of €) | 6/30/2020 | 6/30/2019 |
Consolidated net income for the period | 8,199 | 19,031 |
Income and expenses recognized directly in equity | ||
Non-recyclable | ||
Actuarial gains and losses on IAS 19 liabilities | 759 | 0 |
Actuarial gains and losses on IFRS 2 liabilities | (1,251) | 209 |
Recyclable | ||
Hedging instruments | (1,011) | (1,013) |
Change in translation adjustment | (13,227) | 1,571 |
Net income and gains and losses recognized directly in equity | (6,531) | 19,798 |
PERIOD ENDED JUNE 30, 2020 | Page: 13/27 | |
HALF-YEAR FINANCIAL REPORT | ||
1.4 Consolidated statement of cash flows |
(in thousands of €) | 6/30/2020 | 6/30/2019 |
(6 months) | (6 months) | |
Net income | 8,199 | 19,031 |
Change in amortization/depreciation and provisions on fixed assets and other current | 26,988 | 31,237 |
assets | ||
Allowances and reversals of provisions for liabilities and charges | 900 | 8,531 |
Change in fair value of assets held for sale | 5,202 | 0 |
Changes in fair value of hedging instruments | 1,321 | 1,750 |
Costs of stock options and bonus shares | (1,251) | 209 |
Income from sale of fixed assets and other adjustments | 23 | (94) |
Cash flow after net finance costs and taxes | 41,382 | 60,664 |
Net finance costs | 2,508 | 3,486 |
Tax expenses (including deferred taxes) | 2,785 | 5,691 |
Cash flow before net finance costs and taxes | 46,676 | 69,841 |
Taxes paid | 1,656 | (7,875) |
(Increase) / decrease in inventories | 5,152 | (5,503) |
(Increase) / decrease in trade receivables | 12,634 | (842) |
Increase (decrease) in trade payables and related accounts | 4,104 | (8,767) |
(Increase) / decrease in other assets | (8,578) | (435) |
Increase (decrease) in other liabilities | (962) | (17,362) |
Change in operating WCR | 12,351 | (32,907) |
NET CASH FLOWS FROM OPERATING ACTIVITIES (A) | 60,683 | 29,060 |
Investments | (23,733) | (29,051) |
intangible assets | (10,460) | (12,779) |
tangible assets | (13,628) | (16,309) |
financial fixed assets | 354 | 37 |
Sales | 1,081 | 310 |
intangible assets | 736 | (485) |
tangible assets | 344 | 795 |
financial fixed assets | 0 | 0 |
Increase (decrease) in payables to fixed assets suppliers | (2,522) | (4,889) |
NET CASH FLOWS FROM INVESTMENT ACTIVITIES (B) | (25,175) | (33,630) |
Dividends paid | 48 | (10,686) |
Capital increase | 50 | 39 |
Loan issues | 345 | 353,152 |
Loan repayments | (33,234) | (400,475) |
Net financing interest paid (including finance lease agreements) | (2,543) | (3,367) |
NET CASH FLOWS FROM FINANCING ACTIVITIES (C) | (35,334) | (61,337) |
Effect of exchange rate changes (D) | (3,466) | 1,500 |
NET CHANGE IN CASH AND CASH EQUIVALENTS (A) + (B) + (C) + (D) | (3,292) | (64,407) |
STARTING CASH | 80,481 | 85,556 |
ENDING CASH | 77,190 | 21,149 |
NET CASH | 6/30/2020 | 6/30/2019 |
Bank credit facilities | 300 | 54,704 |
Cash and cash equivalents | 77,490 | 75,853 |
PERIOD ENDED JUNE 30, 2020 | Page: 14/27 | |
HALF-YEAR FINANCIAL REPORT | ||
Total | 77,190 | 21,149 | |||||||
1.5 Statement of changes in shareholders' equity | |||||||||
(in thousands of €) | Capital | Consolidated | Result | Change in | Total | ||||
reserves | translation | ||||||||
adjustment | |||||||||
At 12/31/2018 | 12,581 | 347,030 | 46,820 | (39,669) | 366,761 | ||||
Appropriation of 2018 earnings | 46,819 | (46,819) | 0 | ||||||
Stock options | |||||||||
Dividend distribution | (10,680) | (10,680) | |||||||
2019 consolidated income | 37,328 | 37,328 | |||||||
Actuarial gains and losses | (1,356) | (1,356) | |||||||
Net investment hedge | (6,174) | (6,174) | |||||||
Translation adjustments | 3,192 | 3,192 | |||||||
Capital increase | 15 | 215 | 230 | ||||||
Other changes | (109) | (109) | |||||||
At 12/31/2019 | 12,596 | 375,746 | 37,328 | (36,477) | 389,192 | ||||
Appropriation of 2019 earnings | 37,328 | (37,328) | 0 | ||||||
Stock options | |||||||||
Dividend distribution | (8,818) | (8,818) | |||||||
2020 consolidated income | 8,199 | 8,199 | |||||||
Actuarial gains and losses | (492) | (492) | |||||||
Net investment hedge | (6) | (6) | |||||||
Translation adjustments | (13,227) | (13,227) | |||||||
Capital increase | 3 | 47 | 50 | ||||||
Other changes | (18) | (18) | |||||||
At 6/30/2020 | 12,599 | 403,787 | 8,199 | (49,704) | 374,880 | ||||
PERIOD ENDED JUNE 30, 2020 | Page: 15/27 | |
HALF-YEAR FINANCIAL REPORT | ||
2. Accounting methods and rules
The accounting principles applied in preparing the condensed consolidated financial statements at June 30, 2020, are the same as those used in the consolidated financial statements at December 31, 2019 (which can be viewed on the Group's website: www.guerbet.com).
The Group is not affected by the amendment issued by the IASB on May 28, 2020, to IFRS 16 Leases on COVID-19-related rent concessions given that no temporary rent reductions or payment deferments have been recorded.
The condensed consolidated half-year financial statements at June 30, 2020, were prepared in accordance with IAS 34 Interim Financial Reporting, which allows a selection of appended notes to be presented. The condensed consolidated financial statements must be read in conjunction with the annual consolidated financial statements for the 2019 financial year.
3. Highlights of the first half of 2020
Since February 2020, the Guerbet group has faced the global COVID-19 health crisis. In response, the Group deployed and implemented action plans primarily to ensure and maintain the appropriate level of security for all staff as well as business continuity amid this major uncertainty.
The Group's defined health safety measures resulted in the implementation of a strict health protocol at all production plants as well as the large-scale use of teleworking for all office functions. Relying on suitable tools, the organization in place has allowed the group to ensure that it can fulfill its public health mission on essential products (such as Optiray and Xenetix) and medicinal products of major therapeutic interest (such as Lipiodol and Dotarem) without any disruption of operations.
Lockdown measures are currently being lifted at all Group sites with a gradual return of employees to the headquarters. The number of COVID-19 cases to date within Guerbet remains very low.
Plants maintained their normal production levels throughout the first half of 2020, including during the lockdown periods throughout certain countries.
Supplies of raw materials were not disrupted over this period, which helped maintain the level of activity.
Revenue for the first half of 2020 was down -9% compared with 2019. All regions were affected, except Asia (driven by Japan and Taiwan). Diagnostic Imaging was the most heavily impacted business segment (-13% compared with 2019), while Interventional Imaging increased by +3%. Sales growth was robust in the first quarter of 2020 (up +1%), but it started to slow down in April due to the crisis, with year-on-year decreases in sales of -27% in April and -30% in May. However, growth returned in June, up +2% from 2019, allowing the second quarter of 2020, although down -19%, to end on a positive note.
There was no increase in payment defaults over the period, and payment deferment requests were limited. As of June 30, 2020, delays and extension requests represented a value of approximately €1.9 million out of a total of €118 million in trade receivables. The overall average duration of extensions is approximately 2 months. The impact was especially dramatic in the LATAM region, accounting for nearly 70% of late payments and payment extensions. However, the current situation has no negative effect on the rate of impairment of trade receivables as defined by the Group pursuant to IFRS 9.
The Group has adjusted the management of its operations to this extraordinary situation. As part of the action plans implemented since the crisis began, Guerbet has prioritized cost management and control. Expenditures were cut by around €25 million (excluding non-recurring items) in the first half of 2020 compared with last year, including postponement of certain non-critical projects, reduction of marketing and sales costs (such as conferences, seminars, and travel), and control of support function costs. These decreases add to the savings plans that had already been underway
PERIOD ENDED JUNE 30, 2020 | Page: 16/27 | |
HALF-YEAR FINANCIAL REPORT | ||
before the crisis. Generally speaking, this sharp reduction in costs kept EBITDA at €53.3 million (14.7%), slightly below last year's level. At €25.4 million (7%), EBIT exceeded the 2019 level.
This cost control, coupled with close management of working capital requirements, especially inventories, as well as strict control of investments, with the postponement of non-priority projects, was reflected in the positive free cash flow (FCF) of +€27 million. This visibly improved net debt, totaling €269 million as of June 30, 2020, and allowed Guerbet's financial covenants to be respected. Guerbet has €150 million in unused additional confirmed lines of credit.
The Group has not made significant use of the various government assistance measures in France or abroad. It opted not to resort to partial unemployment in France. Only four of the Group's subsidiaries outside France received government assistance for a total of less than €300 K. Non-recurring expenditures to promote health measures totaled around €2 million.
The Group did not renegotiate its leases or other contracts, such as financing contracts, amid the COVID-19 crisis.
Given the Group's ability to cope with the crisis, the search for indications of impairment losses did not reveal any situations of potential impairment of assets that would trigger impairment tests as of June 30, 2020.
4. Seasonality
There is no significant seasonal aspect to the activity.
5. Dividend payment
A dividend of €0.70 per share was paid to shareholders in July 2020.
6. Management of financial risk
In accordance with its risk hedging policy, the Guerbet group hedges its foreign exchange and interest rate risks on borrowing. On March 27, 2019, the Group negotiated a five-yearvariable-rate syndicated loan of €500 million. The Group is therefore no longer exposed to foreign exchange risk on this loan, but its exposure to interest rate risk remains.
PERIOD ENDED JUNE 30, 2020 | Page: 17/27 | |
HALF-YEAR FINANCIAL REPORT | ||
6.1 Currency risk
6.1.1 Foreign exchange risk exposure and hedging at June 30, 2020
The table below summarizes the Group's main foreign exchange risks:
In millions of € | USD | JPY | KRW | HKD | CLP | CAD | GBP | TRY | CNY | AUD |
Third-party accounting | 3,359 | 1,747 | ||||||||
risk (1) | ||||||||||
Intragroup accounting | 40,088 | 39,747 | 12,314 | 16,601 | 3,386 | (3,579) | (2,973) | 1,572 | 1,643 | |
risk (1) | ||||||||||
Positions before hedging | 43,447 | 39,747 | 12,314 | 16,601 | 3,386 | (3,579) | (2,973) | 1,747 | 1,572 | 1,643 |
Hedges outstanding | (16,665) | (24,863) | (4,609) | |||||||
Net foreign exchange | 28,565 | 14,883 | 12,314 | 11,992 | 3,386 | (3,579) | (2,973) | 1,747 | 1,572 | 1,643 |
position | ||||||||||
(1) Accounting risk includes all assets and liabilities in non-EUR currencies.
Since June 30, 2019:
- The position before hedging in USD decreased from €64 million to €43 million following the reduction of short-term debt in dollars. After a foreign exchange risk hedge was established in April 2020, the net foreign exchange position is €29 million. This hedge is a tunnel of vanilla options for USD 16.7 million with value dates of 6/30/2020 and 12/31/2020 and an impact of €0.269 million as of 6/30 (MtM).
- The foreign exchange position before hedging in Japanese yen (JPY) decreased from €48 million to €40 million due to repayments on financing granted by Guerbet to its Japanese subsidiary. With the establishment of a foreign exchange risk hedge in April 2020, the net foreign exchange position is €15 million. This hedge is a tunnel of vanilla options for JPY 3,000 million with value dates as of 6/30/2020 and 12/30/2020 and an impact of €0.302 million as of 6/30 (MtM).
- The foreign exchange position before hedging in Hong Kong dollars (HKD) decreased from €27 million to €17 million, and a foreign exchange risk hedge in April 2020 reduced the net foreign exchange position to €12 million. This hedge is a tunnel of vanilla options for HKD 40 million with value dates of 6/30/2020 and 12/31/2020 and an impact of €0.076 million as of 6/30 (MtM).
6.1.2 Analysis of sensitivity of the financial result to accounting currency risk at June 30, 2020
The sensitivity analysis is carried out on the non-hedged net balance (accounting risk after deducting hedges outstanding), for the main currencies.
The following table summarizes the impact on the financial result of a 10% variation in these currencies against the euro.
(in thousands of €) | 2020 | 2019 |
USD | 2,857 | 6,432 |
JPY | 1,488 | 4,792 |
KRW | 1,231 | 611 |
HKD | 1,199 | 2,650 |
CNY | 157 | -1 |
AUD | 164 | 0 |
PERIOD ENDED JUNE 30, 2020 | Page: 18/27 | |
HALF-YEAR FINANCIAL REPORT | ||
6.2 Interest rate risk
6.2.1 Interest rate risk exposure and hedging at June 30, 2020
98% of debt is variable-rate.
The choice was made to hedge the syndicated loan for €225 million by establishing interest rate hedging instruments with a starting date delayed by 2 years. This decision is based on the fact that interest rates are expected to remain negative in the short term, which does not justify immediate coverage of the debt, but also by the risk of a significant rise in these rates in the long term.
Below is the breakdown of debt due within one year and in more than one year.
(in thousands of €) | Less than 1 year (1) | More than 1 year | Total | |
Fixed-rate financial liabilities | (0) | (7,682) | (7,682) | |
Variable-rate financial liabilities | (31,905) | (307,217) | (339,122) | |
Fixed-rate financial assets | 32,809 | 32,809 | ||
Variable-rate financial assets | 44,683 | 44,683 | ||
Net position before management (2) | ||||
- | fixed rate | |||
32,809 | (7,682) | 25,127 | ||
- | variable rate | |||
12,778 | (307,217) | (294,439) | ||
Off-balance-sheet(3) | (0) | (225,000) | (225,000) | |
Net position after management | ||||
- | fixed rate | |||
32,809 | (232,682) | (199,873) | ||
- | variable rate | |||
12,778 | (82,217) | (69,439) | ||
(1) | All maturities of variable-rate financial assets and liabilities and maturities in less than one year of fixed-rate financial assets and liabilities. | |||
(2) | Sum of difference of (assets - liabilities) at fixed rates and (assets - liabilities) at variable rates. | |||
(3) | Interest rate swaps (receive variable rates and pay fixed rates). | |||
6.2.2 Analysis of sensitivity of the financial result to interest rate risk at June 30, 2020
Sensitivity is calculated on the unhedged gross debt balance.
99% of this debt is denominated in EUR. As a result, the sensitivity calculated in this note relates only to EUR debt.
On the basis of a 3-month EURIBOR of -0.42% as of June 30, 2020, an increase of 100 basis points would result in a year- on-year increase in EUR debt of around €2 million. A decrease of 100 basis points would not result in a decrease in EUR debt given that the debt base rate has a floor of 0%.
Gross debt in thousands of euros | 3M EURIBOR + 100bp | 3M EURIBOR - 100bp |
345,893 | 347,892 | 340,974 |
PERIOD ENDED JUNE 30, 2020 | Page: 19/27 | |
HALF-YEAR FINANCIAL REPORT | ||
7. Additional information
The geographical information is presented below according to risk and profitability analysis in two subsets, corresponding to the Group's internal organization and Guerbet's various growth models in these markets:
- The main European markets where Guerbet group has been able to build sustainable customer relationships and has a strong position due to its own networks of pharmaceutical sales;
- Other markets.
Europe includes the European countries where the Group is present via its own networks of pharmaceutical sales representatives, namely: Austria, Belgium, France, Germany, Italy, the Netherlands, Portugal, Spain, Switzerland, Turkey, and the United Kingdom.
The non-allocated portion of the operating result corresponds to head-office administrative costs, research and development costs, and indirect industrial costs not attributable to the products, components that can only be allocated on an arbitrary basis to the various sectors.
The Group's support functions and research and development costs are centralized in France.
6/30/2020 in millions of € | European companies in their | Other | Total | ||||||
markets | |||||||||
Revenue: | |||||||||
- | Europe markets | 138.9 | 138.9 | ||||||
- | Other markets | 19.2 | 205.6 | 224.8 | |||||
Total revenue | 158.1 | 205.6 | 363.7 | ||||||
Operating income | 7.6 | 17.8 | 25.4 | ||||||
6/30/2019 in millions of € | European companies in their | Other | Total | ||||||
markets | |||||||||
Revenue: | |||||||||
- | Europe markets | 176.1 | 176.1 | ||||||
- | Other markets | 12.0 | 212.5 | 224.5 | |||||
Total revenue | 188.1 | 212.5 | 400.6 | ||||||
Operating income | 10.2 | 12.0 | 22.2 | ||||||
Breakdown of revenue by product range: | |||||||||
6/30/2020 | 6/30/2019 | ||||||||
X-Ray | 45.0% | 46.2% | |||||||
MRI | 29.5% | 33.4% | |||||||
IRT | 9.9% | 8.7% | |||||||
MD | 10.2% | 8.9% | |||||||
Other | 5.3% | 2.8% | |||||||
Total | 100.0% | 100.0% | |||||||
PERIOD ENDED JUNE 30, 2020 | Page: 20/27 | |
HALF-YEAR FINANCIAL REPORT | ||
8. Descriptive notes (in thousands of euros) | ||
Note 1 - Tangible and intangible fixed assets |
(in thousands of €) | 6/30/2020 | 12/31/2019 | Change |
Tangible fixed assets, gross | 734,764 | 774,698 | (39,934) |
Depreciation | (474,949) | (505,138) | 30,189 |
Impairment | (381) | 3,220 | (3,600) |
Tangible fixed assets, net | 259,435 | 272,779 | (13,345) |
Intangible fixed assets, gross | 280,625 | 269,907 | 10,718 |
Amortization | (87,459) | (80,155) | (7,304) |
Intangible fixed assets, net | 193,166 | 189,754 | 3,412 |
The decrease in tangible fixed assets was mainly due to the reclassification of non-current assets in Canada to "Assets held for sale" on the balance sheet in accordance with IFRS 5 (-€5.3 million).
The €3.4 million increase in intangible fixed assets stemmed from investments in information systems.
Note 2 - Inventories
(in thousands of €) | 6/30/2020 | 12/31/2019 |
Raw materials and spare parts | 52,746 | 59,076 |
Intermediate and finished products, work in progress, and goods | 186,922 | 201,254 |
Gross value | 239,668 | 260,330 |
Provisions | (18,712) | (23,737) |
Net value | 220,956 | 236,593 |
An inventory reduction plan was initiated by the Group in early 2019 to significantly reduce inventory levels. This 3- to 4- year action plan focuses on adjusting plant production plans, optimizing production plant lead-times, and reducing reserve inventories.
Note 3 - Capital
As of December 31, 2019, the parent company's capital was made up of 12,596,161 shares with a par value of €1. The number of Guerbet shares increased over the period from 3,313 to 12,599,474 as of the end of June 2020.
The Group held 17,493 treasury shares as of June 30, 2020.
PERIOD ENDED JUNE 30, 2020 | Page: 21/27 | |
HALF-YEAR FINANCIAL REPORT | ||
Note 4 - Provisions |
2019 | Allowance | Reversals | Reversals | Translation | Change in | 2020 | |
(provision | (provision not | adjustments and | actuarial | ||||
used) | used) | reclassifications | assumptions | ||||
Non-current | 39,303 | 1,216 | (26) | (13) | (7) | (868) | 39,605 |
Of which deferred | 37,202 | 1,196 | (26) | (13) | (7) | (868) | 37,484 |
employee benefits (note 12.2) | |||||||
Current | |||||||
Tax disputes | 220 | 0 | 0 | 0 | (6) | 0 | 213 |
Commercial disputes | 1,261 | 32 | 0 | (120) | 0 | 0 | 1,173 |
Staff-related provisions | 721 | 0 | (202) | 0 | 0 | 0 | 519 |
Miscellaneous risks | 1,920 | 369 | (135) | (221) | (74) | 0 | 1,860 |
Total Current | 4,122 | 401 | (337) | (341) | (80) | 0 | 3,765 |
provisions | |||||||
Total Provisions | 43,425 | 1,617 | (363) | (354) | (87) | (868) | 43,370 |
Note 5 - Borrowing
(in thousands of €) | 6/30/2020 | 12/31/2019 |
Non-current debts, of which | 314,899 | 340,655 |
Special investment reserve (frozen current accounts) | 906 | 1,257 |
IFRS 16 lease liabilities | 7,814 | 8,480 |
Other borrowing | 306,179 | 330,918 |
Current debts, of which | 31,903 | 37,252 |
IFRS 16 lease liabilities | 6,035 | 7,541 |
Other borrowing and current profit-sharing reserves | 25,568 | 28,772 |
Bank facilities | 300 | 939 |
Total financial debt | 346,802 | 377,907 |
Note 6 - Other contingent assets and liabilities
In December 2008, the request for aid filed with OSEO for the French-German "Iseult" research project was approved by the European Commission. The aid agreement provides for funding for half of the expenses incurred, including 39% in the form of repayable advances and 61% in the form of a grant. BPI's coverage of Guerbet's costs is scheduled to end on 30 June 2019. An amendment to the contract was signed in June 2020 by BPI France and Guerbet to revise the conditions for reaching the final milestones and the payment of the associated aid, but also to modify the terms on financial returns in the event that a product resulting from the project is released on the market. Following the signings, Guerbet received the €344 K balance of aid relating to this partnership from BPI France.
Note 7 - Other assets held for sale
As stated in paragraph 11 "Post-closing events," the Group sold its production entity in Canada, LIEBEL-FLARSHEIM CANADA INC, on July 15, 2020.
This entity's assets and liabilities were therefore been presented as of June 30, 2020, on separate lines at the bottom of the balance sheet in accordance with the recommendations of IFRS 5.
PERIOD ENDED JUNE 30, 2020 | Page: 22/27 | |
HALF-YEAR FINANCIAL REPORT | ||
All items were measured at fair value based on the probable disposal value. This resulted in a €5,202 K write-down of net assets. After taking into account the probable loss on disposal, the values reclassified as assets held for disposal represented a net total of €12,871 K, and liabilities represented €3,931 K.
Note 8 - Staff-related costs
8.1 - Stock options
Main characteristics for valuing the share-based payment benefit:
8.1.1 - Characteristics of share-based payments for plans in effect as of June 30, 2020
Grant date | Number | Share price on | Volatility | Risk-free rate | Exercise price | Lock-in period |
granted | grant date | |||||
October 17, 2011 | 530,840 | €16.58 | 35% | 2.77% | €15.40 | 4 years |
November 23, 2011 | 48,000 | €16.80 | 35% | 2.77% | €16.07 | 4 years |
February 20, 2012 | 6,800 | €15.37 | 35% | 2.77% | €15.37 | 4 years |
8.1.2 - Breakdown of the benefit by financial year for plans in progress
Grant date | March 26, | October 17, 2011 | November 23, 2011 | February 20, | Total |
2009 | 2012 | ||||
2015 | 468 | 47 | 7 | 522 | |
2016 | 1 | 1 | |||
Total | 0 | 1,648 | 153 | 24 | 1,825 |
8.1.3 - Impact on balance sheet
The benefit above is recognized for each financial year according to the number of stock options still to be exercised.
PERIOD ENDED JUNE 30, 2020 | Page: 23/27 | |
HALF-YEAR FINANCIAL REPORT | ||
8.2 - Free shares
Under group employee bonus share allocation plan number 2, 26,320 shares were distributed between February 16, 2020, and June 29, 2020.
The main assumptions for the plans in effect as of June 30, 2020, are as follows:
Plan 2 | Plan 2 | Plan 3 | |
Grant date | 9/1/2018 | 12/1/2018 | 7/1/2019 |
Vesting date | 9/1/2020 | 12/1/2020 | 7/1/2022 |
Vesting period | 2 years | 2 years | 3 years |
Price on grant date | 55.8 | 58.4 | 47.70 |
Expected dividend yield | 1.30% | 1.30% | 1.37% |
Risk-free rate | N/A | N/A | N/A |
Volatility | N/A | N/A | 36% |
Employee turnover rate | 0% | 2.06% | 2.06% |
Probability of fulfilling the performance conditions | 96.67% | 96.67% | 100% |
Note 9 - Income tax
The tax expense at June 30, 2020, was calculated using the full-year projected effective tax rate.
A tax expense of €2,579 K was calculated in real terms for the entity in Canada soon to be sold. The projected rate calculated excluding Canada is 22.45%.
The Group's overall effective tax rate was 25.38% at June 30, 2020, compared with 23.02% at June 30, 2019.
Note 10 - Related-party disclosures
10.1 - Relationships with non-consolidated companies
All significant Group subsidiaries are wholly owned and fully consolidated. Transactions between these companies are eliminated.
PERIOD ENDED JUNE 30, 2020 | Page: 24/27 | |
HALF-YEAR FINANCIAL REPORT | ||
10.2 - Remuneration and benefits granted by the Group to the main directors and board members
The main directors make up the Executive Committee. They received the following benefits and compensation in thousands of euros:
Short-term benefits | |
Total gross compensation | 1,625 |
in-kind benefits | 14 |
variable portion 1 | 681 |
Post-employment benefits | |
of which funded supplemental pension contributions | 50 |
of which provisions for retirement benefits (on the balance sheet) | 539 |
Share-based payments 2 | |
Stock options | 0 |
Bonus shares | 181 |
The members of the Board of Directors who are not Executive Committee members received €55 K in compensation. In addition, during the first half of 2020, the Board members received €288 K in attendance fees for the period.
Note 11 - Post-closing events
On July 15, 2020, Guerbet announced the sale of its pharmaceutical site in Montreal, Canada, to MedXL, a specialist in medical devices and sterile pre-filled syringes. The Montreal industrial facility specializes in the filling and finishing of contrast media in the very high-volume manufacture of syringes pre-filled with sterile solutions for third parties, which is not a core business for Guerbet. Guerbet will gradually transfer its contrast agent production operations previous conducted in Montreal to its pharmaceutical sites in France and the US. Guerbet is selling this plant as part of its plans to optimize the group's industrial network. This deal will make Guerbet more competitive by improving capacity utilization at its other manufacturing plants.
The Montreal plant does not represent a major entity or a main, distinct geographical region for the Group. It is also not a cash-generating unit as defined by the Guerbet Group.
Under the sale contract with the buyer, the current outsourcing agreement will be maintained for two years. It is therefore not a single, coordinated plan for the divestiture of an activity.
The Montreal plant was acquired at the same time as the other CMDS Group entities at the end of 2015. This entity was therefore not acquired to be sold.
This sale was therefore considered a divested activity and not a discontinued activity as defined by IFRS 5.
- For each one, the variable portion depends on achieving a number of individual objectives over the course of the previous year. It is adjusted according to the performance of the company or the Group, during that same year, and is calculated on the basis of the salary for December 2019.
- This is the expense recorded for the first half of 2020 (excluding social security contributions) for stock options and bonus shares granted to them (see note 7).
PERIOD ENDED JUNE 30, 2020 | Page: 25/27 | |
HALF-YEAR FINANCIAL REPORT | ||
Report by the statutory auditors on the half-year financial
information
Period from January 1 to June 30, 2020
This is a free translation into English of the statutory auditors' review report issued in French and is provided solely for the convenience of English- speaking readers. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.
To the Shareholders of Guerbet S.A.,
Under the terms of the assignment entrusted to us by your general meeting, and in accordance with Article L. 451-1-2 III of the French monetary and financial code, we performed the following tasks:
- a limited review of Guerbet's condensed consolidated half-year financial statements for the period from 1 January to 30 June 2020, as attached to this report;
- verification of the information provided in the half-year report.
These condensed consolidated half-year financial statements were prepared under the responsibility of your Board of Directors on September 23, 2020 on the basis of the information available at that date in the evolving context of the Covid- 19 crisis and difficulties in assessing its impacts and future prospects. It is our responsibility to express an opinion on these statements on the basis of our limited review.
1. Opinion on the financial statements
We conducted our limited review in accordance with professional standards applicable in France. A limited review primarily consists in talking with members of the management team in charge of accounting and financial matters and in implementing analytical procedures. Such a review is less comprehensive than the investigations required for a full audit under French professional standards. As such, the assurance obtained through a limited review that the financial statements are overall free of any material anomalies represents moderate assurance, which is not as certain as the assurance obtained through an audit.
On the basis of our limited review, we did not discover any material misstatements likely to call into question the compliance of the summary consolidated half-year financial statements with IAS 34 - an IFRS standard as adopted in the European Union relating to interim financial reporting.
2. Specific verification
We also verified the information provided in the half-year activity report, dated as of September 23, 2020, commenting on the condensed consolidated half-year financial statements that were the subject of our limited review.
We have no matters to report as to their fair presentation and consistency with the condensed consolidated half-year financial statements.
PERIOD ENDED JUNE 30, 2020 | Page: 26/27 | |
HALF-YEAR FINANCIAL REPORT | ||
Levallois-Perret et Paris-La Défense, 24 September 2020
The Statutory Auditors
Crowe HAF | Deloitte & Associés |
Marc de PRÉMARE | David KHAROUBI | Jean-François VIAT |
PERIOD ENDED JUNE 30, 2020 | Page: 27/27 | |
HALF-YEAR FINANCIAL REPORT | ||
Statement from the person responsible for the half-year financial
report
I certify, to the best of my knowledge, that the condensed consolidated financial statements for the past half-year period were drawn up in accordance with the applicable accounting standards and fairly present, in all material respects, the assets, liabilities, financial position, and earnings of the company and all the companies included in the consolidation scope and that the attached half-year activity report presents a fair view of any significant events occurring over the first six months of the year, their impacts on the financial statements, the main related-party transactions, and a description of the main risks and uncertainties for the remaining six months of the financial year.
Villepinte, 24 september 2020
David Hale
Chief Executive Officer
Attachments
- Original document
- Permalink
Disclaimer
Guerbet SA published this content on 30 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2020 16:49:08 UTC
